News

The neurologist at Thomas Jefferson University Hospitals discussed the pros and cons of supplemental drugs used to reduce off time in patients with Parkinson disease.

The 2019 update to the 2018 guidelines clarifies prior recommendations and takes into consideration new clinical trial data to offer a comprehensive guide for treatment, from symptom onset through 2 weeks after acute ischemic stroke.

The director of the Cleveland Lou Ruvo Center for Brain Health at Cleveland Clinic discussed the ground that has been made in treating dementia, and how nuance in diagnosis can provide a possible leg up for physicians.

The neurologist at Cleveland Clinic outlines the need to better understand the biology of progressive MS in order to make substantial headway in its treatment.

Neurology News Network for the week ending October 28, 2019.

The chief medical executive at The University of Texas MD Anderson Cancer Center is expected to be named the next commissioner of the FDA by President Donald Trump.

In Part 2 of this interview, Amaal Starling, MD, assistant professor of neurology at Mayo Clinic Scottsdale, discussed what still needs to be done in the migraine space in light of recent advancements and how disease-specific therapies are just the beginning for the field.

The director of the Cleveland Lou Ruvo Center for Brain Health at Cleveland Clinic discussed the diagnostic differences between Lewy body dementia, Alzheimer disease, and other dementias, as well as the importance of proper identification.

In an interview with NeurologyLive, Andrew S. Feigin, MD, details ongoing trials that aim to treat Huntington disease, including the notable SIGNAL trial.

In Part 1 of this interview, Amaal Starling, MD, assistant professor of neurology at Mayo Clinic Scottsdale, shared her experiences with a number of new migraine drugs and devices and the impact that more options will have on clinical practice.

Study data demonstrates that treatment with satralizumab reduces risk of relapses in patients with neuromyelitis optica spectrum disorder.

The breakthrough study is a concrete example of the opportunities that precision medicine present in the pursuit to prevent the onset of or worsening of diseases like Alzheimer dementia.

Bogged down by a decades-long chase for a common pathology, investigators exploring alternative and complimentary theories are pushing to extend their time in the spotlight.

Study results suggest that adherence to individually tailored interventions, including behavioral, dietary, pharmacologic, educational, and other recommendations can have a positive impact on cognition and reduce risk in patients across the clinical spectrum who have a family history of Alzheimer disease.

The staff neurologist at Cleveland Clinic addressed several questions regarding choosing an optimal therapy for patients with MS.

The drug, which is currently approved for single-dose intravenous administration in patients with SMA type 1, is currently being investigated as intrathecal therapy in SMA type 2.

The FDA has granted the go-ahead to Biogen and Alkermes’ diroximel fumarate, which will be marketed as Vumerity, for the treatment of relapsing-remitting and secondary progressive MS, as well as clinically isolated syndrome.

The director of the Center for Spinal Cord Injury Research and co-director of the Spinal Cord Injury Model System Center at Kessler Foundation discussed the secondary medical complications of spinal cord injury and how he and colleagues seek to alleviate them.

A phase 3 study of celecoxib oral solution showed statistically significant improvements in the acute treatment of episodic migraine.

Analysis of long-term safety of intranasal diazepam shows favorable results in children and adolescents with cluster or acute, repetitive seizures.

Robert Fox, MD, reviews the current treatment landscape for progressive multiple sclerosis, and why a focus on inflammation may not be sufficient to slow disease progression.

Although the indication of pimavanserin has provided some relief, more work remains to improve how physicians diagnose, treat, and manage psychosis symptoms.

The benefits of lowering systolic blood pressure for stroke prevention and reducing poststroke disability are numerous, but the ideal target remains elusive.

Robert Fox, MD, discussed the pursuit to identify new imaging biomarkers in an effort to better understand the disease course in progressive multiple sclerosis.

Study results show that deflazacort tops prednisone across multiple checkpoints in patients with Duchenne muscular dystrophy.

Reisa Sperling, MD sat down with NeurologyLive to discuss why she thinks investigational drugs for Alzheimer disease are failing, and what she feels are the most promising treatment avenues.

Krithika Subramanian, PhD discusses the orexin receptor pathway, signals within orexin receptors, and much more surrounding the clinical application of orexin receptor antagonists.

Neurology News Network for the week ending October 26, 2019.